磷酸二酯酶10A IgG:副肿瘤性神经自身免疫的新型生物标志物
该研究描述了7例PDE10A IgG阳性患者,表现为基底节区突触染色,多数合并肿瘤(肺癌、肾癌、胰腺癌),部分出现运动障碍。2例在免疫检查点抑制剂治疗后出现高动力性运动障碍,提示PDE10A IgG是副肿瘤性中枢神经系统自身免疫的新型标志物。
要点
- PDE10A IgG阳性患者常合并肿瘤,以肺癌、肾癌、胰腺癌多见。
- 临床表型以运动障碍为主,包括舞蹈症、投掷症、肌张力障碍和帕金森综合征。
- 免疫检查点抑制剂治疗可能诱发PDE10A IgG相关高动力性运动障碍。
核心结论
- PDE10A IgG定义了一种新型罕见的神经系统自身免疫综合征,扩展了可诊断的副肿瘤性中枢神经系统疾病谱。
研究设计与样本
- 研究描述了Mayo Clinic神经免疫学实验室鉴定的7例PDE10A IgG阳性患者,标本包括血清7份和脑脊液4份。
主要发现
- 患者中位年龄70岁(范围66-76),4例为男性。
- 有临床信息的4例患者均出现运动障碍,其中3例为高动力性(舞蹈症、投掷症、肌张力障碍),1例为帕金森综合征。
- 7例中6例合并肿瘤:肺癌3例(腺癌1、鳞癌1、低分化间叶癌1)、肾腺癌2例、胰腺腺癌1例。
- 2例患者在免疫检查点抑制剂(纳武利尤单抗和帕博利珠单抗)治疗期间出现高动力性运动障碍,其MRI显示FLAIR/T2基底节高信号,脑脊液存在独特寡克隆带,其中1例经皮质类固醇治疗后显著改善。
- 1例患者肾腺癌免疫组化显示PDE10A表达。
临床怎么用
- 对副肿瘤性中枢神经系统综合征患者,尤其合并运动障碍和肿瘤时,可考虑检测PDE10A IgG。
- 接受免疫检查点抑制剂治疗并出现运动障碍的患者,应警惕PDE10A IgG相关自身免疫综合征。
局限性
- 研究样本量小(7例),且部分患者临床信息不完整。
- PDE10A的细胞内定位提示T细胞介导的病理机制,但未直接证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe a novel antibody biomarker of neurologic paraneoplastic autoimmunity specific for phosphodiesterase 10A (PDE10A), a striatum-enriched phosphodiesterase, and to characterize the clinical phenotype of patients with PDE10A immunoglobulin G (IgG). METHODS: We describe 7 patients with autoantibodies specific for PDE10A identified in the Mayo Clinic Neuroimmunology Laboratory. Patient specimens (sera, 7; CSF, 4) produced identical basal ganglia-predominant synaptic staining of murine brain tissue by indirect immunofluorescence. The autoantigen was identified by immunoprecipitation and mass spectrometry as PDE10A, and confirmed by antigen-specific recombinant Western blot and cell-based assays, and immune absorption experiments. RESULTS: The median patient age was 70 years (range 66-76); 4 were men. Four patients with clinical information available had movement disorders (hyperkinetic in 3 [chorea, ballismus, dystonia] and parkinsonism in 1). All patients but one had cancer (lung [adenocarcinoma 1, squamous cell carcinoma 1, poorly differentiated mesenchymal carcinoma 1], renal adenocarcinoma 2, and pancreatic adenocarcinoma 1). Two of the 7 patients developed hyperkinetic movement disorders during treatment with immune checkpoint inhibitors (nivolumab and pembrolizumab), though none of 26 cancer control patients treated with immune checkpoint inhibitors harbored PDE10A IgG in their serum. MRIs from those 2 patients with hyperkinetic movement disorders demonstrated fluid-attenuated inversion recovery/T2 basal ganglia hyperintensities, and their CSF harbored unique oligoclonal bands. One of those 2 patients had substantial improvement after corticosteroids. One patient's renal adenocarcinoma expressed PDE10A by immunohistochemistry. CONCLUSIONS: PDE10A IgG defines a novel rare neurologic autoimmune syndrome and expands the spectrum of diagnosable paraneoplastic CNS disorders. The intracellular location of PDE10A suggests a T-cell-mediated pathology targeting cells displaying MHC1-bound PDE10A peptides.
引用
- Zekeridou A, Kryzer T, Guo Y, et al. Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity. Neurology. 2019. PMID: 31315972. doi:10.1212/WNL.0000000000007971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。